Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to demonstrate that in patients with recuperated/normalized left ventricular function, defined as an ejection fraction (EF) ≥ 50%, after implantation of cardiac resynchronization therapy, device treatment is sufficient and neurohumoral blocker therapy can safely be withdrawn


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02200822
Study type Interventional
Source Hasselt University
Contact
Status Completed
Phase Phase 4
Start date July 2014
Completion date February 2019

See also
  Status Clinical Trial Phase
Completed NCT03456856 - A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction. Phase 4
Completed NCT03901729 - A Trial to Study BAY1753011 in Patients With Congestive Heart Failure Phase 2
Completed NCT02301689 - SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
Completed NCT04915118 - A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Medical Problems Due to Heart Failure (HF) in German Patients With HF
Recruiting NCT04149743 - HEMOTAG® Assessment for Short-term Outcomes of Heart Failure N/A
Recruiting NCT05652218 - REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT) N/A
Completed NCT01936649 - Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. Phase 4
Completed NCT02127307 - Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up. N/A